Crossmark

The production of a recombinant tandem single chain fragment variable capable of binding prolamins triggering celiac disease

Crossref DOI link: https://doi.org/10.1186/s12896-018-0443-0

Published Online: 2018-05-29

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Eggenreich, Britta

Scholz, Elke

Wurm, David Johannes

Forster, Florian

Spadiut, Oliver http://orcid.org/0000-0003-0916-0644
License Information

Text and Data Mining valid from 2018-05-29
More Information

Article History

Received: 13 October 2017

Accepted: 9 May 2018

First Online: 29 May 2018

Ethics approval and consent to participate

: Not applicable.

: Sciotec Diagnostic Technologies GmbH holds a patent for the use of IgY and fragments thereof in CD therapy. FF and ES were employed by Sciotec Diagnostic Technologies GmbH, when this study was conducted.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.